Investment Partners LTD. Sells 79 Shares of Eli Lilly and Company (NYSE:LLY)

Investment Partners LTD. trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 1.2% during the fourth quarter, Holdings Channel.com reports. The fund owned 6,549 shares of the company’s stock after selling 79 shares during the quarter. Eli Lilly and Company accounts for about 1.9% of Investment Partners LTD.’s holdings, making the stock its 13th biggest position. Investment Partners LTD.’s holdings in Eli Lilly and Company were worth $3,818,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the business. JGP Wealth Management LLC increased its position in Eli Lilly and Company by 0.9% during the fourth quarter. JGP Wealth Management LLC now owns 1,843 shares of the company’s stock worth $1,074,000 after acquiring an additional 16 shares during the period. Walkner Condon Financial Advisors LLC increased its position in Eli Lilly and Company by 2.8% during the third quarter. Walkner Condon Financial Advisors LLC now owns 621 shares of the company’s stock worth $334,000 after acquiring an additional 17 shares during the period. Patton Albertson Miller Group LLC increased its holdings in Eli Lilly and Company by 2.8% in the 3rd quarter. Patton Albertson Miller Group LLC now owns 623 shares of the company’s stock valued at $335,000 after buying an additional 17 shares during the period. Valley Wealth Managers Inc. increased its holdings in Eli Lilly and Company by 1.3% in the 3rd quarter. Valley Wealth Managers Inc. now owns 1,280 shares of the company’s stock valued at $688,000 after buying an additional 17 shares during the period. Finally, Sandy Cove Advisors LLC increased its holdings in Eli Lilly and Company by 0.8% in the 4th quarter. Sandy Cove Advisors LLC now owns 2,241 shares of the company’s stock valued at $1,307,000 after buying an additional 17 shares during the period. 82.53% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

LLY has been the topic of several recent analyst reports. DZ Bank lowered shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 target price on the stock. in a report on Wednesday, February 21st. Bank of America raised their target price on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a report on Friday, March 1st. Barclays raised their target price on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a report on Wednesday, February 7th. Citigroup raised their target price on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a report on Tuesday, April 2nd. Finally, TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $728.05.

Eli Lilly and Company Trading Up 1.2 %

Eli Lilly and Company stock traded up $8.64 during mid-day trading on Friday, hitting $733.51. 2,009,249 shares of the stock were exchanged, compared to its average volume of 2,265,427. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. Eli Lilly and Company has a 12 month low of $380.77 and a 12 month high of $800.78. The firm’s fifty day simple moving average is $761.79 and its two-hundred day simple moving average is $666.06. The stock has a market capitalization of $696.95 billion, a price-to-earnings ratio of 126.47, a PEG ratio of 1.58 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.19. The firm had revenue of $9.35 billion during the quarter, compared to analyst estimates of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The company’s revenue was up 28.1% compared to the same quarter last year. During the same quarter last year, the business earned $2.09 EPS. Analysts forecast that Eli Lilly and Company will post 12.51 EPS for the current year.

Insider Activity

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of Eli Lilly and Company stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the sale, the insider now owns 99,333,810 shares in the company, valued at approximately $64,375,262,246.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.13% of the stock is currently owned by company insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.